Toshifumi Suzuki Architect of 7Elevens Global Expansion Dies at 93 VF Corporation Draws Jim Cramers Attention as Potential Fantastic Buying Opportunity After Earnings Dip Oppenheimer Upgrades Outlook on Marvell Technology With Price Target Boost Consumer Price Index Accelerates to 38 in April Marking Highest Level Since May 2023 Waterfield Advisors Equities Head Suggests Staggered Accumulation as Peak Macro Concerns Ease US Manufacturers Slow to Adopt AI and Automation Amid Implementation Hurdles MLYS Q1 2026 Earnings Narrow Beat on Losses as Clinical Pipeline Progress Continues ES Q1 2026 Earnings Slight EPS Miss Amid Utility Operations VELO Q1 2026 Earnings Surprise EPS Beat Drives DoubleDigit Stock Rally Despite Missing Revenue Disclosure SRAD Q1 2026 Earnings EPS Misses Estimates Stock Rises Slightly RPT Q1 2026 Earnings Significant EPS Miss as Net Loss of 043 per Share Reported MS Q1 2026 Earnings Earnings Beat by 1092 as EPS Surges to 343 HCICU Holds Steady at 1004 A SPAC Unit Showing Stability Amid Market Uncertainty Blaize Holdings Inc BZAI Surges 1156 Key Levels and Market Dynamics Atlanticus Holdings Preferred Stock ATLCP Climbs 089 as Price Approaches Key Resistance Zone SP Global Inc SPGI Eases 158 as Market Digests Steady Fundamentals Five Point Holdings FPH Edges Lower as Stock Tests Key Support at 468 Government to Offload Up to 2 Stake in Coal India via OFS Floor Price Set at Rs 412 JVA Q4 2019 Earnings Coffee Holding Co Misses EPS Estimates by Wide Margin Novartis NVS Holds Gains Near 151 as Pharmaceutical Sector Shows Stability Chery to Enter Japans EV Market with Minicar Following BYDs Strategy Morgan Stanley Adjusts Price Target for Jazz Pharmaceuticals Microsoft Faces Headwinds Amid SaaSmaggedon Market Turmoil PutinXi Talks Could Revive Stalled Power of Siberia 2 Gas Pipeline as Iran Conflict Shakes Energy Markets EEOC May End DecadesOld Demographic Data Collection Requirement Reshaping Workplace Discrimination Enforcement Eli Lillys NextGeneration Obesity Drug Retatrutide Shows Positive Results in Pivotal Trial Novartis Upgrades FullYear Outlook Raises Sales and Profit Guidance